The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00160056|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : May 12, 2015
Hypoglycaemia unawareness is a common complication in patients with type 1 diabetes and with insulin-treated type 2 diabetes of long duration. The loss of autonomic symptoms to hypoglycemia does not solely depend on loss of adrenaline responses.Differences in sensitivity to catecholamines may also be involved.
Reconciling the data on β2-adrenergic receptor polymorphism to those on loss of β-adrenergic sensitivity in diabetic patients with hypoglycemia unawareness, we hypothesize that hypoglycemia unawareness is at least partly the result of desensitization of the β2-adrenergic receptor and that patients who are homozygous for arginine at codon 16 are particularly susceptible for this desensitization process, whereas patients who are homozygous for glycine at codon 16 are resistant for desensitization.
- To determine whether, and if so to what extent, antecedent hypoglycemia reduces β2-adrenergic sensitivity in healthy subjects with Arg16 homozygosity.
- To investigate whether or not healthy subjects with Gly16 homozygosity are resistant to desensitization
- To confirm that antecedent hypoglycemia reduces the heart rate response to isoproterenol and to assess to what extent this reduced response is mediated by impairments in baroreflex sensitivity.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Hypoglycemia Unawareness||Procedure: Hypoglycemia||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity in Subjects With Homozygous Arg16 and gly16 Polymorphism of the β2-adrenergic Receptor|
|Study Start Date :||April 2005|
|Actual Primary Completion Date :||April 2009|
|Actual Study Completion Date :||April 2009|
Intrerfvention is a hypoglycemic stimulus
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00160056
|Radboud University Nijmegen Medical Centre|
|Nijmegen, Gelderland, Netherlands, 6500HB|
|Principal Investigator:||Paul Smits, PhD, MD||Radboud University|